REG - Cizzle Biotechnology - Final results for the year ended 31 December 2023

Cizzle Biotechnology HoldingsAnnouncement

30/04/2024 09:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd5816Ma&default-theme=true

RNS Number : 5816M  Cizzle Biotechnology Holdings PLC  30 April 2024

30 April 2024

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Final results for the year ended 31 December 2023

 

Cizzle Biotechnology, the UK based diagnostics developer, announces the
publication of the Company's Annual Report and Financial Statements for the
year ended 31 December 2023.

The Annual Financial Report is available via
http://www.rns-pdf.londonstockexchange.com/rns/5816M_1-2024-4-30.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/5816M_1-2024-4-30.pdf)  and
will shortly be available to view on the Company's website
at: https://cizzlebiotechnology.com (https://cizzlebiotechnology.com)

 

Enquiries:

 

 Cizzle Biotechnology Holdings plc  Via IFC Advisory
 Allan Syms (Executive Chairman)

 

 Allenby Capital Limited - Joint Broker and Financial Adviser      +44(0) 20 3328 5656
 John Depasquale
 George Payne

 

 Novum Securities Limited - Joint Broker  +44(0) 20 7399 9400
 Colin Rowbury

 Jon Bellis

 

 IFC Advisory Limited - Financial Public Relations  +44(0) 20 3934 6630
 Tim Metcalfe
 Florence Chandler

 

About Cizzle Biotechnology

Cizzle is developing a blood test for the early detection of lung cancer. The
Company is a spin- out from the University of York, founded in 2006, around
the work of Professor Coverley and colleagues. Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a variant of
CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein
involved in DNA replication, and the targeted CIZ1B variant is highly
correlated with early-stage lung cancer. For more information, please see
https://cizzlebiotechnology.com (https://cizzlebiotechnology.com)

You can also follow the Company through its twitter account @CizzlePlc and on
LinkedIn

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DOCEAPLEDENLEEA